Almac Discovery and Elasmogen to Share Anti-ROR-1 VNAR Data at American Association of Cancer Annual Meeting | 20.03.2019

Craigavon, N.I., UK, 20 Mar 2019 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Elasmogen a biotech company developing next generation therapeutic biologics, today announced they will present a poster on their VNAR-based protein drug conjugates research targeting ROR1 at the upcoming American Association […]

Elasmogen Licenses NDure™ Half-life Extension Technology to ImmunoForge | 07.01.2019

Novel soloMER based albumin binder will be used for two therapeutic fusion proteins™ Aberdeen, Scotland and Seoul, Korea; January 7th 2019:  Elasmogen Ltd, developer of next generation soloMER biologics, announced today that ImmunoForge has entered a license agreement to Elasmogen’s proprietary NDure half-life extension technology for use in two non-disclosed targets.  ImmunoForge will be responsible […]

Elasmogen winner of BioFIT 2018 Start-up Slams | 07.12.2018

  Lille, 5 December 2018 – Elasmogen wins another prestigious award during the 7th Edition of BioFIT. BioFIT is one of Europe’s leading business conventions for technology transfer, academia-industry collaborations and early-stage innovations in the field of Life Sciences. It is also becoming an important marketplace for seed investment in Life Sciences by facilitating early-stage financing deals and gives participants an opportunity to access information about current events and trends in […]